Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.
Case: A 73-Year-Old Man with EGFR+ NSCLC
Clinical Presentation:
Past Medical History:
Social History:
Initial Clinical Workup and Diagnosis:
Physical Examination
Pulmonary Function Tests
Imaging Studies:
Diagnostic Procedure:
Neoadjuvant Therapy and Surgical Resection:
Surgical Pathology Report:
Six Months Later:
Second Line Systemic Therapy:
Repeat Imaging at 8 Weeks:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Joshua K. Sabari, MD.
This video features a discussion on the case of a 73-year-old man with a 50 pack-year smoking history who presented with a persistent nonproductive cough, dyspnea on exertion, and a 10-pound unintentional weight loss over 3 months. His medical history was significant for coronary artery disease, hypertension, hyperlipidemia, and chronic obstructive pulmonary disease (COPD) treated with inhalers. Imaging revealed a 4.2 x 3.1-cm speculated right upper lobe lung mass and enlarged hilar and subcarinal lymph nodes concerning for malignancy. Biopsy confirmed lung adenocarcinoma.
After neoadjuvant chemotherapy with cisplatin, pembrolizumab, and pemetrexed, plus surgical resection, he was found to have stage IIA lung cancer. Six months later he developed scattered pulmonary nodules suspicious for metastatic disease. Biopsy confirmed recurrent metastatic lung adenocarcinoma, and molecular testing identified an exon 21 L858R EGFR mutation.
He was started on osimertinib 80 mg orally daily and had an initial response. He will continue routine follow-up with his oncologist for recurrent metastatic EGFR-mutant non–small cell lung cancer.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More